

EXPERIENCE IN THE TREATMENT OF UTERINE FIBROIDS WITH ULIPRISTAL ACETATE.

Abstract ID : 2474

Submitted by : Ainur Tuletova the 2017-01-30 07:40:02

Category : SEUD CONGRESS 2

Typology : Poster

Status : Validated

Authorisation to disclose : Yes/Oui

Actualy: In recent years, the ulipristal acetate decreased of bleeding in patients with uterine myoma and the main indication for surgical treatment of fibroids are big size of tumor and the presence of pain. So, we need to accumulate clinical effectiveness of ulipristal acetate for the treatment of uterine fibroids with other symptoms.

The aim: to investigate the clinical efficacy of ulipristal acetate 5 mg on the main symptoms of uterine fibroids.

Materials and methods: The study involved 26 patients with uterine myoma in age from 20 to 50 years ($42 \pm 5,1$ years). Menorrhagia was defined by PBAC. Pain was assessed by VAS. Uterine fibroids type determined according to the classification of FIGO (2011). The ulipristal acetate 5 mg used from the 1st day of m.c. continuously for 3 months.

Results: The main symptom was abdominal pain of varying intensity in 15 (57.7%) cases. Polymenorrhea observed in 7 (27%). Infertility in 4 (15.3%). Often, a combination of marked symptoms - 9 (34.6%), so polymenorrhea and pain symptom in 5 (55.6%) patients, pain in the abdomen, feeling the pressure of the bladder and frequent urination in 4 (44.6%) patients. Reduced hemoglobin was seen in 12 (46.1%) of women, anemia was mild in 10 (83.3%), in 2 (16.7%) cases were moderate anemia (hemoglobin less than 90 g/l). According sonography in 13 (50%) was myoma type FIGO 5, 10 (38.5%) patients had myoma type FIGO 6, in 2 (7.7%) - type FIGO 8 and 1 (3.8%) patients a myoma type FIGO 2 - 5.

Increased uterine volume to 8-12 weeks encountered in most cases - in 15 (57.7%) women, increasing up to 5-7 weeks in 9 (34.6%) of 13-16 weeks and up to 2 in (7.7 %) cases.

The use of ulipristal acetate 5 mg in all patients with menorrhagia normalized menstrual cycle (until treatment PBAC 100 - amenorrhea throughout the entire period of treatment). The intensity of pain symptoms before therapy VAS - 6 points, after the end of therapy, the pain symptom was absent - 0 points. The use of ulipristal acetate 5 mg in combination with antianemic therapy contributed to the normalization of blood counts and anemia treatment.

The tolerance of the drug was good, without complaints in (23 - 79.5%). In 3 (11.5%) of patients reported adverse effects such as hot flushes, headaches, emotional disorders. After treating these complaints independently stopped.

By results of US, the majority of patients 15 (61.5%), there is a decrease in the volume of tumor by 9%, decrease in uterine volume by 24.5%. In all cases, the size of the ovaries and ovarian reserve were not changed.

Conclusion: Thus, the main clinical manifestations of uterine fibroids showed the absence of indications for surgical treatment. In view of the clinical efficacy and good tolerability of the drug should be mainly conservative treatment of uterine fibroids, especially in women who do not realize their reproductive plans.

Keywords : Myoma, treatment, ulipristal acetate, clinical efficacy.

Authors :

References : , , ,

Authors

Tuletova Ainur 1, Doschanova Aikerm 1, Shegenov Galym 1,

1. Obstetrics and gynecology, Medical University Astana, Astana, KAZAKHSTAN

Authors (raw format)

Ainur Tuletova - email : a_tuletova@mail.ru Institution : Medical University Astana Department : Obstetrics and gynecology City : Astana Country : KAZAKHSTAN Speaker : Yes

Aikerm Doschanova - email : aikerm54@mail.ru Institution : Medical University Astana Department : Obstetrics and gynecology City : Astana Country : KAZAKHSTAN Speaker : No

Galym Shegenov - email : g_shegenov@mail.ru Institution : Medical University Astana Department : Obstetrics and gynecology City : Astana Country : KAZAKHSTAN Speaker : No

